Frontiers in drug delivery最新文献

{"title":"Editorial: Recent advancements and developments in targeted drug delivery systems for cancer diagnosis and therapy.","authors":"Abhishesh Kumar Mehata, Bipin Chaurasia, Ana Isabel Fraguas-Sánchez","doi":"10.3389/fddev.2025.1654788","DOIUrl":"https://doi.org/10.3389/fddev.2025.1654788","url":null,"abstract":"","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"5 ","pages":"1654788"},"PeriodicalIF":0.0,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145151604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies for delivering drugs across the blood-brain barrier for the treatment of neurodegenerative diseases.","authors":"Xiaopei Zhang, Manfei Fu, Yuanfei Wang, Tong Wu","doi":"10.3389/fddev.2025.1644633","DOIUrl":"10.3389/fddev.2025.1644633","url":null,"abstract":"<p><p>The blood-brain barrier (BBB) restricts development of drug delivery systems for brain, which hinders the potential applications of numerous pharmaceutical agents for treating central nervous system (CNS) diseases. A number of drug delivery systems have been developed to enhance the capacity of drugs to cross BBB. A detailed introduction of the structure and function of BBB was given based on the mechanism of BBB, while comparing with the pathological changes of BBB in neurodegenerative diseases (NDDs), including activation of endothelial cells, the loose of tight junction and increase of BBB permeability. The liposomes, polymer nanoparticles and other novelty approaches for treating NDDs were summarized. Here, we provide a novel perspective to classify the strategies of drug delivery system as passive targeting and active targeting according to their mechanisms. The potential of clinical translational for drug delivery systems in NDDs was explored and underscored the imperative of safety and verification through clinical trials. In summary, this review proposed current developments of drug delivery systems and discussing the potentials of drug delivery systems in clinical translational which bring new breakthroughs for treating NDDs.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"5 ","pages":"1644633"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoencapsulation of morin hydrate with BSA for sustained drug release in colorectal carcinoma cells: experimental and computational approach.","authors":"Sanju Kumari Singh, Amit Kumar Srivastav, Sunaina Chaurasiya, Sunita Patel, Umesh Kumar, Hitesh Kulhari","doi":"10.3389/fddev.2025.1623317","DOIUrl":"10.3389/fddev.2025.1623317","url":null,"abstract":"<p><p>Colorectal cancer is among the most redundant cancer of the gastrointestinal tract, with its burden expected to rise 60% by 2030. Morin hydrate (MH) is a bioflavonoid with anticancer attributes. However, the implementation of MH is limited due to its hydrophobic properties, along with poor stability and bioavailability. Protein-based nanoparticle may encapsulate the drug and this complex can enhance the drug efficacy and delivery to colorectal carcinoma cells. To investigate the molecular interactions between BSA and MH, the Lamarckian genetic approach was used. In the current study, we prepared BSA encapsulated MH nanoparticles by desolvation method. The characterization of the nanoparticles was done by XRD, DSC, TGA and FTIR was performed to corroborate the results. MHNPs were spherical with a particle size of 90 nm determined by TEM and a zeta potential of -11 ± 5.90 mV. BSA nanoparticles improve the thermal stability and sustained release profile of Morin Hydrate, enabling its application as a phytochemical-based anticancer nanocarrier. The antioxidant test of MHNPs showed higher radical scavenging ability than MH. Additionally, our release investigations show that drug release occurs from the matrix of the nanoformulation to reach the target site efficiently. An increase in the anticancer potential was shown by an <i>in vitro</i> cytotoxicity assay in comparison to MH. These data suggest that MH was successfully encapsulated and enhanced solubility, resulting in greater bioavailability.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"5 ","pages":"1623317"},"PeriodicalIF":0.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nickel nanoparticles: a novel platform for cancer-targeted delivery and multimodal therapy.","authors":"Fengyu Wang, Sen Tong, Xuan Ma, Huan Yang, Tianbao Zhang, Kunrong Wu, Junzi Wu","doi":"10.3389/fddev.2025.1627556","DOIUrl":"10.3389/fddev.2025.1627556","url":null,"abstract":"<p><p>Traditional cancer treatment methods often encounter limitations, such as poor targeting, low bioavailability, and high systemic toxicity. These challenges have led researchers to explore alternative therapeutic strategies. Nickel nanoparticles (NiNPs), owing to their distinctive physicochemical properties and tunable biocompatibility, have attracted considerable attention in cancer therapy and drug delivery applications. These nanomaterials demonstrate excellent magnetic properties, photothermal conversion capabilities, catalytic activity, and potential for multifunctionality and targeted drug delivery via surface modification. This review highlights recent advancements in the use of NiNPs for cancer treatment, emphasizing their advantages as drug carriers that enhance the bioavailability, targeting, and therapeutic efficacy of anticancer agents. Additionally, the synergistic applications of NiNPs in multimodal therapies, including magnetic hyperthermia, photothermal therapy, and chemodynamic therapy, are discussed, as well as their potential as theranostic platforms. Although nickel-based nanodelivery systems show significant promise for clinical translation, issues related to biosafety, degradation metabolism, and long-term toxicity remain and require further investigation to support their clinical application.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"5 ","pages":"1627556"},"PeriodicalIF":0.0,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gene hydrogel platforms for targeted skin therapy: bridging hereditary disorders, chronic wounds, and immune related skin diseases.","authors":"Liangtao Li","doi":"10.3389/fddev.2025.1598145","DOIUrl":"10.3389/fddev.2025.1598145","url":null,"abstract":"<p><p>Gene therapy, a pivotal cornerstone in biomedical research, has emerged as a transformative approach for addressing a wide spectrum of dermatologic conditions, including hereditary disorders, chronic wounds, and immune related skin diseases. The skin, with its expansive surface area and regenerative capacity, serves as an ideal platform for localized gene delivery. However, conventional gene therapy strategies face critical limitations, such as high costs, suboptimal transfection efficiency, immunogenicity, and off-target effects. In this context, gene hydrogels have emerged as an innovative paradigm, offering tailored physicochemical and biological functionalities to overcome these challenges. Gene hydrogels are distinguished by their tunable morphologies (e.g., particulate or bulk gel configurations), which enable precise control over therapeutic release kinetics and spatial distribution. Their three-dimensional polymeric networks recapitulate the extracellular matrix, functioning as bioactive scaffolds that enhance tissue regeneration, facilitate cell migration, and accelerate wound healing. By integrating stimuli-responsive polymers, these hydrogels achieve spatiotemporal control of gene delivery, improving target specificity while minimizing systemic exposure. Furthermore, their inherent biocompatibility and biodegradability mitigate immunogenic risks and prevent long-term residue accumulation, addressing pivotal safety concerns in clinical translation. This review systematically examines the multifaceted advantages of gene hydrogels, including their ability to bypass the stratum corneum barrier, protect genetic payloads from enzymatic degradation, and sustain localized therapeutic effects over extended periods. Recent advancements in \"smart\" hydrogels, responsive to pathological cues such as pH fluctuations or matrix metalloproteinase overexpression, further underscore their potential in personalized medicine. By synergizing material science with gene-editing technologies, gene hydrogels represent a revolutionary leap toward precision dermatologic therapies. Future challenges, such as scalable manufacturing and dynamic regulatory mechanisms, are critically analyzed alongside opportunities in intelligent material design and interdisciplinary innovation. This comprehensive analysis positions gene hydrogels as a cornerstone for next-generation dermatologic therapeutics, bridging the gap between laboratory innovation and clinical impact.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"5 ","pages":"1598145"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced drug delivery systems for oral squamous cell carcinoma: a comprehensive review of nanotechnology-based and other innovative approaches.","authors":"Alain Herrada Céspedes, Montserrat Reyes, Javier O Morales","doi":"10.3389/fddev.2025.1596964","DOIUrl":"10.3389/fddev.2025.1596964","url":null,"abstract":"<p><p>Oral cancer, particularly oral squamous cell carcinoma (OSCC), poses significant challenges due to its aggressiveness, high metastatic potential, and resistance to conventional therapies. Recent advancements in drug delivery systems (DDS), including nanotechnology, intelligent hydrogels, lipid nanoparticles, and photodynamic therapy (PDT), offer innovative solutions for targeted treatment. These DDS utilize tumor-specific stimuli, such as pH variations, reactive oxygen species (ROS), and enzymatic activity, to achieve precise drug release while minimizing systemic toxicity. Cutting-edge technologies, such as microelectromechanical systems (MEMS) and artificial intelligence (AI), are enhancing the precision and personalization of DDS. Combination therapies integrating chemotherapy, PDT, and immunotherapy show promise in overcoming current limitations. Despite significant progress, challenges remain in scalability, patient-specific customization, and safety assessments. This review synthesizes the state-of-the-art in DDS for OSCC, highlighting future directions and the need for interdisciplinary collaboration to improve therapeutic outcomes and patient quality of life.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"5 ","pages":"1596964"},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic mechanotherapy and sonopermeation guided by mathematical modeling for solid tumor treatment.","authors":"Marina Koutsi, Triantafyllos Stylianopoulos, Fotios Mpekris","doi":"10.3389/fddev.2025.1549098","DOIUrl":"10.3389/fddev.2025.1549098","url":null,"abstract":"<p><p>The progression of tumors and their response to treatment are significantly influenced by the presence of elevated mechanical solid stress. This solid stress compresses intratumoral blood vessels, leading to reduced blood flow (hypoperfusion) and insufficient oxygen levels (hypoxia), both of which hinder the delivery of oxygen and therapeutic agents. As a result, these conditions promote tumor growth, resistance to treatment, and ultimately undermine the effectiveness of therapies. To address these challenges, strategies like mechanotherapeutics and ultrasound sonopermeation have been developed to enhance blood flow and improve drug delivery to tumors. Mechanotherapy aims to reduce the mechanical stress and stiffness within tumors, helping to decompress vessels and restore normal perfusion. Ultrasound sonopermeation temporarily increases the permeability of blood vessel walls in a non-invasive manner, boosting blood flow and improving the delivery of therapeutic drugs. Here, we developed a mathematical model to explore the combined effects of mechanotherapeutics and sonopermeation on optimizing nano-immunotherapy efficacy. The model integrates complex interactions between key components involved in tumor progression, including tumor cells, immune cells, and vascular elements such as endothelial cells, angiopoietins, and vascular endothelial growth factor. To assess the model's validity, its predictions for key parameters, including tumor volume, functional vascular density, and hypoxia levels, were compared with experimental data, demonstrating a strong correlation, and confirming the accuracy of the mathematical framework. Furthermore, we carried out a parametric analysis to establish critical guidelines aimed at optimizing both the sequence and timing of experimental procedures. Specifically, we investigated the therapeutic outcomes of two treatment scenarios: applying sonopermeation first, followed by nano-immunotherapy, and <i>vice versa</i>. Also, we determined the optimal time interval between the application of sonopermeation and the commencement of the combined nano-immunotherapy regimen to maximize therapeutic efficacy.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"5 ","pages":"1549098"},"PeriodicalIF":0.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing healthcare: the transformative potential of nanotechnology in medicine.","authors":"Lavan K Durgam, Terry L Oroszi","doi":"10.3389/fddev.2025.1556426","DOIUrl":"10.3389/fddev.2025.1556426","url":null,"abstract":"<p><p>Medical science stands on the brink of transformation thanks to nanotechnology's fast-paced development, which promises major advancements. Working with materials at the nanoscale within a 1-100 nm range allows scientists to tap into special physicochemical characteristics that open up new possibilities in diagnostics, drug delivery, and regenerative medicine. The review explores nanotechnology's revolutionary effects on healthcare by highlighting its roles in medical imaging applications and diagnostic procedures, drug delivery systems, tissue engineering, and vaccine development. The design principles of nanomaterials, which encompass synthesis methods alongside functionalization and characterization techniques, are presented here. This review analyzes the impact of artificial intelligence in nanomedicine alongside the enduring effects of nanomaterials and related ethical and safety issues. The review further combines multiple study findings to offer a thorough overview of nanotechnology's medical applications while suggesting research and clinical translation paths.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"5 ","pages":"1556426"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The stealth effect from a medicinal chemist perspective: definition and updates.","authors":"Domenico Fuoco","doi":"10.3389/fddev.2025.1564120","DOIUrl":"10.3389/fddev.2025.1564120","url":null,"abstract":"<p><p>In recent years, there has been a significant increase in literature on emerging nanotechnologies, including nanoparticles, nanorobots, and exosomes, for various therapeutic applications. Additionally, politically driven research initiatives aimed at accelerating COVID-19 vaccine development have further amplified interest in nanoparticles as drug delivery systems. This article provides a personal perspective on the scientific claims surrounding nanoparticles by: (i) analyzing the historical evolution of their terminology, (ii) reviewing the most cited publications in the field, and (iii) offering a professional assessment to guide the next-generation of medicinal chemists. A key aspect of this discussion is the stealth effect, which refers to the ability of nanoparticles to evade recognition and clearance by the immune system, thereby prolonging their circulation time in the bloodstream. This property is essential for enhancing the efficacy of nanoparticle-based therapeutics by improving bioavailability and ensuring targeted drug delivery to diseased tissues. Furthermore, the continuing improvement in ligand-molecules and other functional tools have developed novel strategies and brand-new definition of delivery systems, such as Trojan Horse and Nanorobots.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"5 ","pages":"1564120"},"PeriodicalIF":0.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poor-tasting pediatric medicines: Part 1. A scoping review of their impact on patient acceptability, medication adherence, and treatment outcomes.","authors":"Sejal R Ranmal, Jennifer Walsh, Catherine Tuleu","doi":"10.3389/fddev.2025.1553286","DOIUrl":"10.3389/fddev.2025.1553286","url":null,"abstract":"<p><strong>Background: </strong>Many medicines for children taste bitter and unpleasant, presenting a significant barrier to effective pharmacotherapy. Anecdotally, this issue is widely recognized; however, empirical evidence on the consequences of unpalatable medicines remains scarce and fragmented. The objective of this scoping review was to investigate the impact of poor tasting pediatric medicines on patient acceptability, medication adherence, and/or treatment outcomes.</p><p><strong>Methods: </strong>A literature search was performed in MEDLINE/PubMed, EMBASE and CINAHL from inception to June 2023. Eligibility criteria included interventional or observational studies conducted in children aged 0-18 years (population), administered an unpalatable oral medicine (exposure), with any reported impact on patient acceptability, medication adherence, and treatment effects (outcomes). Study screening and data extraction was completed using a standardized form on Covidence.</p><p><strong>Results: </strong>After searching 2,282 citations and reviewing 429 full-text papers, 225 articles were included in the final analysis. The impact of poor-tasting medicines was observed across 77 diseases or indications, with 156 different unpalatable medicinal products identified. Outcomes were most frequently linked to reduced patient acceptability, with 64% of articles reporting rejection responses, the need for strategies to aid administration (from positive reinforcement to physical restraint and forced administration), and impacts on prescribing practices (e.g., use of non-first line alternative therapies). Medication adherence impacts were reported in 27% of the reviewed studies, where poor taste was reported as a barrier to adherence in chronic diseases and correlated with incomplete dose administration in acute conditions. A small number of studies linked palatability with treatment outcomes, including viral suppression in HIV and seizure control in epilepsy.</p><p><strong>Conclusion: </strong>This review highlights the widespread adverse impact of poor-tasting pediatric medicines on patient experiences and outcomes, though the true extent of the issue may still be underreported. The problem affects children worldwide, across all age groups, and is frequently noted by parents, caregivers, and healthcare professionals in both clinical and domiciliary settings. These findings emphasize the need for the development and prescription of more palatable medicines for children, as well as the advancement of more universal taste-masking strategies to address this widespread problem.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"5 ","pages":"1553286"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}